Table 1.
Patient characteristics (FAS)
| Characteristics | Venetoclax + Obinutuzumab N = 10 |
|---|---|
| Age, years | |
| Median (range) | 69.5 (52–76) |
| ≥ 65, n (%) | 6 (60.0) |
| ≥ 75, n (%) | 2 (20.0) |
| Sex, n (%) | |
| Male | 6 (60.0) |
| Female | 4 (40.0) |
| Diagnosis and stage | |
| CLL, n (%) | 9 (90.0) |
| Binet stage, n (%)a | |
| A | 3 (33.3) |
| B | 4 (44.4) |
| C | 2 (22.2) |
| SLL, n (%) | 1 (10.0) |
| Lugano classificationb, n (%)c | |
| IV | 1 (100.0) |
| 17p deletion, n (%) | |
| Present | 1 (10.0) |
| Absent | 9 (90.0) |
| ECOG performance status, n (%) | |
| 0 | 10 (100.0) |
| TLS risk category, n (%) | |
| High | 2 (20.0) |
| Medium | 5 (50.0) |
| Low | 3 (30.0) |
| Total CIRS score | |
| Median (range) | 5.5 (0–12) |
| > 6, n (%) | 5 (50.0) |
| Tumor bulkd, cm | |
| < 5, n (%) | 9 (90.0) |
| ≥ 5 and < 10, n (%) | 1 (10.0) |
| Creatinine clearance, mL/min | |
| Median (range) | 64.755 (34.85–94.81) |
| < 70, n (%) | 6 (60.0) |
CIRS, cumulative illness rating scale; CLL, chronic lymphocytic leukemia; ECOG, Eastern Cooperative Oncology Group; FAS, full analysis set; SLL, small lymphocytic lymphoma; TLS, tumor lysis syndrome
aProportion among patients with CLL
bModified version of the Ann Arbor staging system
cProportion among patients with SLL
dCalculated using the largest diameter among measurable lesions